PBH
Prestige Consumer Healthcare Inc.Price & Indicators
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders NeutralIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted Diluted EPS non-GAAP | $1.14 | Q3 FY2026 | — |
| Covenant-defined leverage ratio | 2.6 | as of December 31, 2025 | — |
| Free cash flow non-GAAP | $208.8M | first nine months of fiscal 2026 | — |
| Shares repurchased | 0.8M | Q3 FY2026 | — |
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
Drug Manufacturers - Specialty & Generic — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
PBH
this stock
Prestige Consumer Healthcare Inc.
|
$2.29B | -21.7% | -4.3% | 12.4 | 6.2% |
|
TAK
Takeda Pharmaceutical Co Ltd
|
$53.49B | +7.4% | — | — | 0.2% |
|
GALDY
Galderma Group AG/ADR
|
$51.02B | +4.9% | — | — | 0.0% |
|
JHPCY
Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR
|
$45.13B | — | — | — | 0.0% |
|
HLN
Haleon plc
|
$42.76B | -3.6% | — | — | 0.3% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| PBH | +2.2% | +1.2% | -25.4% | +2.2% | -21.7% |
| SPY | -0.2% | +0.8% | +7.4% | -0.2% | +9.3% |
| vs SPY | +2.3% | +0.4% | -32.8% | +2.3% | -31.0% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.